CC-671 is primarily used in the field of cancer research, particularly in the study of tumor growth and metastasis associated with mutations in the RAF protein. It functions as a potent and selective inhibitor of mutated RAF protein kinase activity, which plays a critical role in cell signaling pathways associated with cancer progression. Researchers utilize CC-671 to investigate its potential in disrupting these pathways, thereby inhibiting the proliferation of cancer cells. Its application extends to preclinical studies where it is evaluated for its efficacy in reducing tumor size and preventing the spread of cancer to other tissues. Additionally, CC-671 is explored for its potential to enhance the effectiveness of existing cancer therapies, such as chemotherapy or targeted treatments, when used in combination to increase efficacy and reduce side effects. Its role in targeting specific molecular mechanisms makes it a valuable tool in the development of novel anticancer drugs.